A retrospective study analysing improvement in Overall survival in patients with myelofibrosis in the era of ruxolitinib
Latest Information Update: 01 Feb 2022
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 25 Jan 2022 Results (N=844) published in the Cancer
- 08 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology